These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21047953)

  • 1. Selective binding of bladder muscarinic receptors in relation to the pharmacokinetics of a novel antimuscarinic agent, imidafenacin, to treat overactive bladder.
    Yamada S; Seki M; Ogoda M; Fukata A; Nakamura M; Ito Y
    J Pharmacol Exp Ther; 2011 Feb; 336(2):365-71. PubMed ID: 21047953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography.
    Yoshida A; Maruyama S; Fukumoto D; Tsukada H; Ito Y; Yamada S
    Life Sci; 2010 Jul; 87(5-6):175-80. PubMed ID: 20598326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary Excretion Contributes to Long-Lasting Blockade of Bladder Muscarinic Receptors by Imidafenacin: Effect of Bilateral Ureteral Ligation.
    Ito Y; Kuraoka S; Endo S; Takahashi A; Onoue S; Yamada S
    J Pharmacol Exp Ther; 2017 Jan; 360(1):69-74. PubMed ID: 27831487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice.
    Oki T; Maruyama S; Takagi Y; Yamamura HI; Yamada S
    Eur J Pharmacol; 2006 Jan; 529(1-3):157-63. PubMed ID: 16316647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of muscarinic receptor binding by the novel radioligand, [(3)H]imidafenacin, in the bladder and other tissues of rats.
    Kuraoka S; Ito Y; Wakuda H; Shinozuka K; Onoue S; Yamada S
    J Pharmacol Sci; 2016 Jul; 131(3):184-9. PubMed ID: 27430986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland.
    Kobayashi F; Yageta Y; Segawa M; Matsuzawa S
    Arzneimittelforschung; 2007; 57(2):92-100. PubMed ID: 17396619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion.
    Oki T; Toma-Okura A; Yamada S
    J Pharmacol Exp Ther; 2006 Mar; 316(3):1137-45. PubMed ID: 16282521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo demonstration of muscarinic receptor binding activity of N-desethyl-oxybutynin, active metabolite of oxybutynin.
    Oki T; Kawashima A; Uchida M; Yamada S
    Life Sci; 2005 Apr; 76(21):2445-56. PubMed ID: 15763076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder.
    Oki T; Kageyama A; Takagi Y; Uchida S; Yamada S
    J Urol; 2007 Feb; 177(2):766-70. PubMed ID: 17222678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
    Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
    Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The N-oxide metabolite contributes to bladder selectivity resulting from oral propiverine: muscarinic receptor binding and pharmacokinetics.
    Yamada S; Ito Y; Taki Y; Seki M; Nanri M; Yamashita F; Morishita K; Komoto I; Yoshida K
    Drug Metab Dispos; 2010 Aug; 38(8):1314-21. PubMed ID: 20483954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice.
    Ito Y; Oyunzul L; Yoshida A; Fujino T; Noguchi Y; Yuyama H; Ohtake A; Suzuki M; Sasamata M; Matsui M; Yamada S
    Eur J Pharmacol; 2009 Aug; 615(1-3):201-6. PubMed ID: 19446545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological effects of imidafenacin (KRP-197/ONO-8025), a new bladder selective anti-cholinergic agent, in rats. Comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in the Morris water maze task.
    Kobayashi F; Yageta Y; Yamazaki T; Wakabayashi E; Inoue M; Segawa M; Matsuzawa S
    Arzneimittelforschung; 2007; 57(3):147-54. PubMed ID: 17469649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Muscarinic Receptor Binding in Rat Bladder Urothelium and Detrusor Muscle by Intravesical Solifenacin.
    Ito Y; Kashiwabara M; Yoshida A; Hikiyama E; Onoue S; Yamada S
    Biol Pharm Bull; 2016; 39(7):1167-71. PubMed ID: 27374291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder.
    Oki T; Kimura R; Saito M; Miyagawa I; Yamada S
    J Urol; 2004 Nov; 172(5 Pt 1):2059-64. PubMed ID: 15540789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice.
    Oki T; Sato S; Miyata K; Yamada S
    Br J Pharmacol; 2005 May; 145(2):219-27. PubMed ID: 15753946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Up-regulation of nicotinic and muscarinic receptor mRNA in rat bladder by repeated administration of nicotine in relation to the pharmacokinetics.
    Yamamoto N; Yoshida A; Taki Y; Onoue S; Kagawa Y; Yamada S
    Life Sci; 2011 Aug; 89(9-10):343-8. PubMed ID: 21762705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo characterization of muscarinic receptors in peripheral tissues: evaluation of bladder selectivity of anticholinergic agents to treat overactive bladder.
    Maruyama S; Hasuike N; Suzuki K; Yamada S
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):463-71. PubMed ID: 18074121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological properties of TD-6301, a novel bladder selective muscarinic receptor antagonist.
    McNamara A; Pulido-Rios MT; Sweazey S; Obedencio GP; Thibodeaux H; Renner T; Armstrong SR; Steinfeld T; Hughes AD; Wilson RD; Jasper JR; Mammen M; Hegde SS
    Eur J Pharmacol; 2009 Mar; 605(1-3):145-52. PubMed ID: 19168050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative functional selectivity of imidafenacin and propiverine, antimuscarinic agents, for the urinary bladder over colon in conscious rats.
    Muraki Y
    Naunyn Schmiedebergs Arch Pharmacol; 2015 Nov; 388(11):1171-8. PubMed ID: 26216447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.